Discovery of biaryl anthranilides as full agonists for the high affinity niacin receptor

Journal of Medicinal Chemistry

Volumn 50, Issue 25, 2007, Pages 6303-6306

  Shen, Hong C ^a   Ding, Fa Xiang ^a   Luell, Silvi ^a   Forrest, Michael J ^a   Carballo Jane, Ester ^a   Wu, Kenneth K ^a   Wu, Tsuei Ju ^a   Cheng, Kang ^a   Wilsie, Larissa C ^a   Krsmanovic, Mihajlo L ^a   Taggart, Andrew K ^a   Ren, Ning ^a   Cai, Tian Quan ^a   Deng, Qiaolin ^a   Chen, Qing ^a   Wang, Junying ^a   Wolff, Michael S ^a   Tong, Xinchun ^a   Holt, Tom G ^a   Waters, M Gerard ^a   Hammond, Milton L ^a   Tata, James R ^a   Colletti, Steven L ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTHRANILIDE DERIVATIVE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; G PROTEIN COUPLED RECEPTOR; NICOTINIC ACID; PROTEIN GPR109A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOLYSIS; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; VASODILATATION;

AMIDES; ANIMALS; ANTHRANILIC ACIDS; ARYL HYDROCARBON HYDROXYLASES; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; MICE; MICROSOMES, LIVER; RADIOLIGAND ASSAY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 37049006087     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm700942d     Document Type: Article

References (39)

1. (a) Elvehjem, C. A.; Madden, R. J.; Strong, F. M.; Wooley, D. W. The isolation and identification of the anti-black tongue factor. J. Biol. Chem. 1938, 123, 137-149.
2. (b) Holman, W. I.; De Lange, D. J. Significance of tryptophane in human nicotinic acid metabolism. Nature 1950, 165, 112-113.
3. (a) Mack, W. J.; Selzer, R. H.; Hodis, H. N.; Erickson, J. K.; Liu, C. R.; Liu, C. H.; Crawford, D. W.; Blankenhorn, D. H. One-year reduction and longitutudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Stroke 1993, 24, 1779-1783.
4. (b) Nikkila, E. A.; Viikinkoski, P.; Valle, M.; Frick, M. H. Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: A seven year prospective angiographic study. Br. Med. J. 1984, 289, 220-223.
5. (c) Pritzker, L. B. Do lipid lowering drugs reduce the risk of coronary heart disease. Crit. Rev. Clin. Lab. Sci. 1998, 35, 603-621.
6. (d) Carlson, L. A. Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 2005, 258, 94-114.
7. (a) Knopp, R. H. Drug treatment of lipid disorders. N. Engl. J. Med. 1999, 341, 498-511.
8. (b) Offermanns, S. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target. Trends Pharmacol. Sci. 2006, 27, 384-390.
9. (a) The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA, J. Am. Med. Assoc. 1975, 231, 360-381.
10. (b) Canner, P. L.; Berge, K. G.; Wenger, N. K.; Stemler, J.; Friedman, L.; Prineas, R. J.; Friedewald, W. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J. Am. Coll. Cardiol. 1986, 8, 1245-1255.
11. Carlson, L. A.; Rosenhamer, G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with Clofibrate and nicotinic acid. Acta Med. Scand. 1988, 203, 405-418.
12. Brown, B. G.; Zhao, X.-Q.; Chait, A.; Fisher, L. D.; Cheung, M.; Morse, J. S.; Dowdy, A. A.; Marino, E. K.; Bolson, E. L.; Alaupovic, P.; Frohlich, J.; Albers, J. J. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 2001, 345, 1583-1591.
13. Taylor, A. J.; Sullenberger, L. E.; Lee, H. J.; Lee, J. K.; Grace, K. A. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2. Circulation 2004, 110, 3512-3517.
14. (a) Wise, A.; Foord, S. M.; Fraser, N. J.; Barnes, A. A.; Elshourbagy, N.; Eilert, M.; Ignar, D. M.; Murdock, P. R.; Steplewski, K.; Green, A.; Brown, A. J.; Dowell, S. J.; Szekeres, P. G.; Hassall, D. G.; Marshall, F. H.; Wilson, S.; Pike, N. B. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 2003, 278, 9869-9874.
15. (b) Tunaru, S.; Kero, J.; Schaub, A.; Wufka, C.; Blaukat, A.; Pfeffer, K.; Offermanns, S. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 2003, 9, 352-355.
16. Herk, T.; Brussee, J.; Nieuwendijk, A. M. C. H.; Klein, P. A. M.; Ijzerman, A. P.; Stannek, C.; Brumeister, A.; Lorenzen, A. Pyrazole derivative as partial agonists for the nicotinic acid receptor. J. Med. Chem. 2003, 46, 3945-3951.
17. (a) Campbell, M.; Hatley, R. J.; Heer, J. P.; Mason, A. M.; Pinto, I. L.; Rahman, S. S.; Smith, I. E. D. (GlaxoSmithKline). Chemical Compounds. Patent WO 2005016867, 2005.
18. (b) Campbell, M.; Hatley, R. J.; Heer, J. P.; Mason, A. M.; Nicholson, N. H.; Pinto, I. L.; Rahman, S. S.; Smith, I. E. D. (GlaxoSmithKline). 2-Substituted benzoic acid derivatives as GPR109A receptor agonists. Patent WO 2005016870, 2005.
19. (c) Pinto, I. L.; Rahman, S. S.; Nicholson, N. H. (GlaxoSmithKline). Novel Compounds. Patent WO 2005077950, 2005.
20. (d) Campbell, M.; Mason, A. M.; Pinto, I. L.; Pollard, D. R.; Smith, I. E. D. (GlaxoSmithKline). Anthranilic acid derivatives and their use in treatment of diseases of lipid metabolism, in particular dyslipidaemia. Patent WO 2006085108, 2006.
21. (e) Mason, A. M.; Pinto, I. L.; Rahman, S. S. (GlaxoSmithKline). Anthranilic acid derivatives active at the GPR109A receptor. Patent WO 2006085111, 2006.
22. (f) Hatley, R. J.; Mason, A. M.; Pinto, I. L.; Smith, I. E. D. (GlaxoSmithKline). Anthranilic acid derivatives as GPR109A receptor agonists. Patent WO 2006085112, 2006.
23. (g) Pinto, I. L.; Simpson, J. K. (GlaxoSmithKline). Chemical compounds. Patent WO 2006085113, 2006.
24. (h) Hatley, R. J. D.; Pinto, I. L. Patent WO 2006/045564 A1, 2006.
25. (i) Hatley, R. J. D.; Pinto, I. L. (GlaxoSmithKline). Xanthine derivatives with HM74A receptor activity. Patent WO 2006045565, 2006.
26. (j) Heer, J. P.; Smith, I. E. D. (GlaxoSmithKline). Xanthine derivatives as selective HM74A agonists. Patent WO 2007017265, 2007.
27. (k) Boatman, D. P.; Schrader, T. O.; Semple, G.; Skinner, P. J.; Jung, J.-K. (Arena). Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof. Patent WO 2006069242, 2006.
28. (l) Semple, G.; Schrader, T.; Skinner, P. J.; Colletti, S. L.; Gharbaoui, T.; Imbriglio, J. E.; Jung, J.-K.; Liang, R.; Raghavan, S.; Schmidt, D.; Tata, J. R. (Arena and Merck). A preparation of tetrazole derivatives, useful as modulators of RUP25 receptor. Patent WO 2005044816, 2005.
29. (m) Colletti., S. L., Beresis, R. T.; Chen, W.; Tata, J. R.; Shen, H. C.; Marley, D. M.; Deng, Q.; Frie, J. L.; Ding, F. (Merck). Niacin receptor agonists, compositions containing such compounds and methods of treatment. Patent WO 2006052555, 2006.
30. (n) Colletti, S. L.; Tata, J. R.; Shen, H. C.; Ding, F.-X.; Frie, J. L.; Imbriglio, J. E.; Chen, W. (Merck). Niacin receptor agonists, compositions containing such compounds and methods of treatment. Patent WO 2006057922, 2006.
31. (o) Raghavan, S.; Colletti, S. L.; Ding, F.-X.; Shen, H.; Tata, J. R.; Lins, A. R.; Smenton, A. L.; Chen, W.; Schmidt, D. Y.; Tria, G. S. (Merck). Niacin receptor agonists, compositions containing such compounds and methods of treatment. Patent WO 2006002557, 2006.
32. (p) Colletti, S. L.; Shen, H.; Tata, J. R.; Szymonifka, M. J. (Merck). Niacin receptor agonists, compositions containing such compounds and methods of treatment. Patent WO 2007027532, 2007.
33. (q) Colletti, S. L.; Imbriglio, J. E.; Beresis, R. T.; Frie, J. L. (Merck). Niacin receptor agonists, compositions containing such compounds and methods of treatment. Patent WO 2007035478, 2007.
34. (r) Dehmlow, H.; Grether, U.; Kratochwil, N. A.; Narquizian, R.; Panousis, C.; Peters, J.-U. (Hoffmann-La Roche). Novel anthranilic acid derivatives. Patent US 20060281810, 2006.
35. (s) Dehmlow, H.; Grether, U.; Kratochwil, N. A.; Narquizian, R.; Panousis, C. (Hoffmann-La Roche). Novel thiophene derivatives which are HM74A agonists. Patent US 20070072873, 2007.
36. (t) Palani, A.; Su, J.; Xiao, D.; Huang, X.; Rao, A. U.; Chen, X.; Tang, H.; Qin, J.; Huang, Y.; Aslanian, R. G.; Mckittrick, B. (Schering). Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia. Patent WO 2006124490, 2006.
37. (u) Cao, G.; Xue, C.-B.; Anand, R.; Huang, T.; Kong, L.; Glenn, J.; Feng, H. (Incyte). Disubstituted thienyl compounds and their use as pharmaceuticals. Patent WO 2007015744, 2007.
38. Cheng, K.; Wu, T.-J.; Wu, K. K.; Sturino, C.; Metters, K.; Gottesdiener, K.; Wright, S. D.; Wang, Z.; O'Neil, G.; Lai, E.; Waters, M. G. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilationin mice and humans. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6682-6687.
39. See Supporting Information for the detailed preparation of all analogs.